联合血管内阻断腔静脉与主动脉对正常血容量和失血性休克猪的血流动力学及代谢影响的随机研究
阻断期间,两个REBOA组系统平均动脉压和心输出量高于两个REBOA+REBOVC组(p<0.05);再灌注60分钟后两组间MAP和心输出量无统计学显著差异。再灌注期间,两个REBOA+REBOVC组动脉乳酸和钾浓度高于两个REBOA组(p<0.05)。内器官损伤标志物无重大差异。再灌注1小时后存活率在正常血容量REBOA和REBOA+REBOVC组分别为86%和100%,在失血性休克相应组分别为67%和83%。结论认为,在充分复苏下,REBOA+REBOVC可实现可接受的血流动力学稳定和短期存活,但必须考虑其相比REBOA更严重的血流动力学和代谢影响。
要点
- 在正常血容量和失血性休克猪中,REBOA+REBOVC阻断期间系统MAP和心输出量低于单纯REBOA(p<0.05)。
- 再灌注60分钟后,REBOA与REBOA+REBOVC组间MAP和心输出量无统计学显著差异。
- 再灌注期间,REBOA+REBOVC组动脉乳酸和钾浓度高于REBOA组(p<0.05)。
- 再灌注1小时存活率:正常血容量REBOA 86%、REBOA+REBOVC 100%;失血性休克REBOA 67%、REBOA+REBOVC 83%。
- 内器官损伤标志物在REBOA与REBOA+REBOVC间无重大差异。
适用人群与场景
- 麻醉猪,正常血容量或严重失血性休克(控制性动脉放血至收缩压50 mmHg,相当于血容量的40-50%)。
- 研究场景为实验动物模型,非人类急诊或ICU患者。
诊断标准与关键阈值
- 严重失血性休克模型:控制性动脉放血至收缩压50 mmHg,相当于血容量的40-50%。
- REBOA zone 1或REBOA+REBOVC zone 1阻断45分钟,随后复苏再灌注3小时。
处置流程与药物剂量
- 第一步:在正常血容量或严重失血性休克猪中,随机分配至REBOA zone 1或REBOA+REBOVC zone 1。
- 第二步:进行45分钟阻断。
- 第三步:随后进行3小时复苏和再灌注。
- 原文未提及具体药物剂量、给药途径、频次或目标值。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:前瞻性、随机、实验动物研究(基础科学研究,治疗性)。
- 人群:正常血容量或严重失血性休克猪。
- 干预与对照:REBOA zone 1 vs REBOA+REBOVC zone 1,阻断45分钟,随后3小时复苏再灌注。
- 主要终点结果:阻断期间,两个REBOA组系统MAP和心输出量高于两个REBOA+REBOVC组(p<0.05);再灌注60分钟后,MAP和心输出量组间无统计学显著差异。
- 关键次要终点:再灌注期间,两个REBOA+REBOVC组动脉乳酸和钾浓度高于两个REBOA组(p<0.05);内器官损伤标志物无重大差异。
- 不良事件:再灌注1小时存活率在正常血容量REBOA和REBOA+REBOVC组分别为86%和100%,在失血性休克相应组分别为67%和83%。
证据类型、等级与局限
- 证据类型:前瞻性、随机、实验动物研究(基础科学研究,治疗性)。
- 证据等级:原文标注LEVEL OF EVIDENCE: Prospective, randomized, experimental animal study. Basic science study, therapeutic.
对床旁实践的改变
- 在猪模型中,REBOA+REBOVC可维持阻断期间可接受的血流动力学稳定和短期存活,但相比单纯REBOA有更严重的代谢影响(乳酸和钾升高),临床决策时需权衡。
- 该结果来自动物实验,不能直接改变人类急诊或ICU的常规做法,需进一步临床研究验证。
- 适用人群:原文未提及人类适用人群;不适用人群:原文未提及。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Mortality from traumatic retrohepatic venous injuries is high and methods for temporary circulatory stabilization are needed. We investigated survival and hemodynamic and metabolic effects of resuscitative endovascular balloon occlusion of the aorta (REBOA) and vena cava inferior (REBOVC) in anesthetized pigs.
METHODS: Twenty-five anesthetized pigs in normovolemia or severe hemorrhagic shock (controlled arterial bleeding in blood bags targeting systolic arterial pressure of 50 mm Hg, corresponding to 40-50% of the blood volume) were randomized to REBOA zone 1 or REBOA+REBOVC zone 1 (n = 6-7/group) for 45 minutes occlusion, followed by 3-hour resuscitation and reperfusion. Hemodynamic and metabolic variables and markers of end-organ damage were measured regularly.
RESULTS: During occlusion, both the REBOA groups had higher systemic mean arterial pressure (MAP) and cardiac output (p < 0.05) compared with the two REBOA+REBOVC groups. After 60 minutes reperfusion, there were no statistically significant differences between the two REBOA groups and the two REBOA+REBOVC groups in MAP and cardiac output. The two REBOA+REBOVC groups had higher arterial lactate and potassium concentrations during reperfusion, compared with the two REBOA groups (p < 0.05). There was no major difference in end-organ damage markers between REBOA and REBOA+REBOVC. Survival after 1-hour reperfusion was 86% and 100%, respectively, in the normovolemic REBOA and REBOA+REBOVC groups, and 67% and 83%, respectively, in the corresponding hemorrhagic shock REBOA and REBOA+REBOVC groups.
CONCLUSION: Acceptable hemodynamic stability during occlusion and short-term survival can be achieved by REBOA+REBOVC with adequate resuscitation; however, the more severe hemodynamic and metabolic impacts of REBOA+REBOVC compared with REBOA must be considered.
LEVEL OF EVIDENCE: Prospective, randomized, experimental animal study. Basic science study, therapeutic.
参考来源
- Wikström MB, Smårs M, Karlsson C, et al. A randomized porcine study of the hemodynamic and metabolic effects of combined endovascular occlusion of the vena cava and the aorta in normovolemia and in hemorrhagic shock. J Trauma Acute Care Surg. 2021. PMID: 33496552. doi:10.1097/TA.0000000000003098
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。